Comparable Outcomes With and Without Neoadjuvant Therapy in High-Risk Melanoma
Patients with high-risk, stage III melanoma have similar outcomes whether they undergo surgery upfront or receive immunotherapy prior to surgery, a study suggests.
Patients with high-risk, stage III melanoma have similar outcomes whether they undergo surgery upfront or receive immunotherapy prior to surgery, a study suggests.
Personalized ctDNA monitoring can predict outcomes during and after treatment in patients with advanced melanoma, a study suggests.
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Periadjuvant pembrolizumab may improve outcomes over adjuvant pembrolizumab alone in patients with resectable stage III-IV melanoma, a phase 2 study suggests.
The application is supported by data from the phase 3 CheckMate76K trial.
Methotrexate use may be associated with an increased risk of skin cancer, but more research is needed.
The FDA has granted breakthrough therapy designation to mRNA-4157/V940 in combination with pembrolizumab to treat melanoma.
Nivolumab plus relatlimab can produce durable responses in patients with advanced melanoma whose disease progressed on anti-PD-1/PD-L1 regimens.
Phase 3 trials for metastatic breast cancer, lung cancer, and melanoma do not include leptomeningeal disease-specific endpoints.
Survival outcomes of advanced melanoma are worse for AYAs than for older adults, a study suggests.